Aytu biopharma announces addition of fourth patent license for ar101/enzastaurin

This fourth patent for ar101/enzastaurin strengthens and broadens the intellectual property portfolio surrounding the treatment of inherited vascular disorders including vascular ehlers-danlos syndrome (veds). multiple patent families filed in key global markets englewood, co / accesswire / september 14, 2022 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the addition of a fourth patent to the intellectual property suite surrounding ar101/enzastaurin.
AYTU Ratings Summary
AYTU Quant Ranking